- Home
- AMPL vs ADPT Comparison
AMPL vs ADPT Comparison
Compare AMPL & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- ADPT
- Stock Information
- Founded
- AMPL 2012
- ADPT 2009
- Country
- AMPL United States
- ADPT United States
- Employees
- AMPL N/A
- ADPT N/A
- Industry
- AMPL EDP Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMPL Technology
- ADPT Health Care
- Exchange
- AMPL Nasdaq
- ADPT Nasdaq
- Market Cap
- AMPL 1.5B
- ADPT 1.4B
- IPO Year
- AMPL 2021
- ADPT 2019
- Fundamental
- Price
- AMPL $11.61
- ADPT $10.38
- Analyst Decision
- AMPL Buy
- ADPT Strong Buy
- Analyst Count
- AMPL 10
- ADPT 7
- Target Price
- AMPL $13.40
- ADPT $10.57
- AVG Volume (30 Days)
- AMPL 1.3M
- ADPT 1.3M
- Earning Date
- AMPL 08-07-2025
- ADPT 07-31-2025
- Dividend Yield
- AMPL N/A
- ADPT N/A
- EPS Growth
- AMPL N/A
- ADPT N/A
- EPS
- AMPL N/A
- ADPT N/A
- Revenue
- AMPL $306,601,000.00
- ADPT $189,527,000.00
- Revenue This Year
- AMPL $12.82
- ADPT $24.46
- Revenue Next Year
- AMPL $10.82
- ADPT $20.25
- P/E Ratio
- AMPL N/A
- ADPT N/A
- Revenue Growth
- AMPL 8.56
- ADPT 8.61
- 52 Week Low
- AMPL $7.37
- ADPT $2.99
- 52 Week High
- AMPL $14.88
- ADPT $10.87
- Technical
- Relative Strength Index (RSI)
- AMPL 46.53
- ADPT 62.28
- Support Level
- AMPL $11.37
- ADPT $9.90
- Resistance Level
- AMPL $12.32
- ADPT $10.85
- Average True Range (ATR)
- AMPL 0.44
- ADPT 0.48
- MACD
- AMPL -0.20
- ADPT -0.02
- Stochastic Oscillator
- AMPL 12.44
- ADPT 68.39
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).